Ozenoxacin

Ozenoxacin is a quinolone antibiotic.¹ It is active against clinical isolates of S. pyogenes, P aeruginosa, and P. acnes and clinical isolates of antibiotic-sensitive and -resistant S. aureus, S. epidermidis, and S. pneumoniae (MIC₅₀s = 0.00625-1.56 mg/L). Ozenoxacin inhibits S. aureus DNA gyrase and topoisomerase IV (IC₅₀s = 4.5 and 0.617 mg/L, respectively). It reduces insulin- or 5α-dihydroxy testosterone-induced triglyceride production and lipid droplet formation in primary hamster sebocytes when used at a concentration of 30 µM.² Ozenoxacin (30 µg/ml) decreases heat-killed C. acnes-induced increases in IL-6 and IL-8 production in HEKa primary human keratinocytes and IL-1β, IL-6, IL-8, and TNF-α production in THP-1 monocytes.³ Topical application of ozenoxacin (1%) decreases skin lesion bacterial counts in a mouse model of burn infection caused by S. aureus.¹ Formulations containing ozenoxacin have been used in the treatment of S. aureus- or S. pyogenes-associated impetigo.

WARNING This product is not for human or veterinary use.

1. Yamakawa, T., Mitsuyama, J., and Hayashi, K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J. Antimicrob. Chemother. 49(3), 455-465 (2002).

2. Kitano, T., Koiwai, T., Fujikawa, K., et al. Ozenoxacin suppresses sebum production by inhibiting mTORC1 activation in differentiated hamster sebocytes. J. Dermatol. 51(9), 1187-1198 (2024).

3. Tabara, K., Tamura, R., Nakamura, A., et al. Anti-inflammatory effects of ozenoxacin, a topical quinolone antimicrobial agent. J. Antibot. (Tokyo) 73(4), 247-254 (2020).